Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | REN | P00797 | 6/20 | 0.45 |
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1502287 | 0.85 | DRD4 (0.52) | — | |
| SCHEMBL3607018 | 0.85 | DRD4 (0.52) | — | |
| SCHEMBL13853942 | 0.85 | DRD4 (0.52) | — | |
| SCHEMBL17152556 | 0.81 | DRD4 (0.50) | GRNSORT1 | |
| SCHEMBL7400619 | 0.79 | UTS2R (0.62) | MAPK1 | |
| SCHEMBL7415020 | 0.79 | UTS2R (0.62) | MAPK1 | |
| SCHEMBL7402928 | 0.79 | UTS2R (0.62) | MAPK1 | |
| SCHEMBL7403794 | 0.77 | UTS2R (0.55) | MAPK1CTSKRENBCHEACHE | |
| SCHEMBL4185698 | 0.77 | KMT2A (0.40) | CTSSCTSKCTSLCTSB | |
| SCHEMBL4318397 | 0.76 | CTSK (0.49) | MAPK1CTSKRENBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | TRPV4, TRPC4, TRPV1 | MAPK1 1920/4885CTSS 1717/4885CTSK 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.